VC-backed Crispr Therapeutics raises $56 mln for IPO
Crispr Therapeutics, a provider of gene-editing technology, has debuted its IPO after pricing its 4 million shares at $14 per share. The stock began trading October 19, 2016 on the NASDAQ under the ticker symbol "CRSP." Citigroup, Piper Jaffrey and Barclays are serving as the lead underwriters. Crispr's backers included Franklin Templeton Investments, New Leaf Venture Partners, Clough Capital Partners LP and Wellington Capital Management LLP.
19 October 2016•2 mins read
